OncoDNA and Synlab partner to facilitate access to comprehensive biomarker testing for cancer therapy selection in Germany

Synlab laboratories to perform OncoDEEP® biomarker test to help doctors decide on the most effective treatment for their cancer patients.

OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases, announced today a partnership with Synlab, europe’s leading clinical laboratory and medical diagnostic services provider. integrating OncoDEEP in their portfolio, Synlab laboratories in Germany will perform comprehensive testing of solid tumors and deliver decision support for oncologists. The technology transfer is ongoing, with the objective of processing the first patient samples early q2.

“We are delighted to transfer our OncoDEEP technology to further enhance Synlab in the field of molecular diagnostics for clinical oncology,” stated Bernard Courtieu, CEO of OncoDNA. “Biomarker testing has the potential to improve patient outcomes and health quality. Improving access to these tests should be a priority worldwide. This collaboration will further support the uptake of precision medicine across Germany.” 

Through this collaboration, OncoDNA and Synlab will provide doctors with high-quality, pan-cancer biomarker testing for the treatment of their patients. Compared to single biomarker testing, OncoDEEP is a comprehensive test used to predict patient response to a wide range of approved and experimental therapies in a single test. 

The test is based on the analysis of over 600 genes and also includes the measurement of complex genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB), microsatellite instability (MSI) and loss of heterozygosity (LOH) to determine for example whether a patient may be eligible for targeted treatment or immunotherapy. In certain cancer types, such as HER2-positive breast cancer, immunohistochemistry (IHC) analyses will also be performed to measure protein expression and reveal patients eligibility to anti-cancer drugs.

Synlab will build upon its extensive expertise in diagnostics to provide OncoDNA tissue-based biomarker tests in Germany. Its laboratories based in Jena and Mannheim will be responsible for running OncoDEEP®, building up on OncoDNA’s technical and scientific knowledge. The laboratories will operate the complete process, from the test ordering to the clinical recommendation reporting, in compliance with the regulatory requirements applicable for the reimbursement of the tests by the health insurance companies in Germany. 

Dr. Christian Mayer, head of human genetics, pathology and cytology at SYNLAB Germany, underlines the innovative advancement of the new test: “OncoDEEP is a real asset for oncology diagnostics offering in Germany. Particularly in comparison to a single biomarker test, the chance to comprehensively test and predict patient responses to a variety of treatments provides significant benefit to patients and doctors and ultimately delivers accurate decision support on the most effective treatment options.”

The clinical interpretation will be supported by OncoDNA proprietary database, and patient-specific reports will be made available on OncoKDM® online platform. To date, OncoDNA database counts no less than 4,500,000 genetic variants, 1,150 cancer drugs, and data from 7,000 clinical trials.

ABOUT ONCODNA

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late stage cancer patients, but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA grew into a corporate group of companies with world-renown expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data analysis software and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – BioSequence and IntegraGen – are based in Spain and France. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories. 

For further information, connect with us on LinkedInFacebook.

ABOUT SYNLAB

Synlab Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doc-tors, hospitals and clinics, governments and corporates.

Providing the leading level of service within the industry, SYNLAB is the partner of choice for rou-tine and specialty diagnostics in human and veterinary medicine. The Group continuously inno-vates medical diagnostic services for the benefit of patients and customers.

SYNLAB operates in 36 countries across four continents and holds leading positions in most mar-kets, regularly reinforcing the strength of its network through a proven acquisition strategy. More than 30,000 employees, including over 2,000 medical experts, contribute every day to the Group’s worldwide success.

SYNLAB performed around 600 million laboratory tests and achieved revenues of €3.76 billion in 2021.

More information can be found on www.synlab.com.

MEDIA CONTACTS

Sandrine Rubay, Marketing Officer, OncoDNA.

SYNLAB MEDIA CONTACT

Diana Tabor, FTI Consulting (+49 (0) 151 46693856)

You may also be interested in these resources

Scientific Application Note

MELANOMA: In a retrospective study of patients with advanced disease who achieved a complete response to immunotherapy, cessation of therapy was associated with a 27% risk of subsequent disease progression.

LONG-TERM OUTCOMES AND RESPONSES TO RETREATMENT IN PATIENTS WITH MELANOMA TREATED WITH PD-1 BLOCKADE Allison Betof Warner, et JP Journal Of Clinical Oncology Volume 38, Issue 15 PURPOSE To analyze long-term outcomes after treatment discontinuation of anti–programmed...

Share This